Grifols, S.A. (NASDAQ:GRFS) Shares Acquired by Black Creek Investment Management Inc.

Black Creek Investment Management Inc. raised its stake in shares of Grifols, S.A. (NASDAQ:GRFS) by 7.7% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 12,339,314 shares of the biotechnology company’s stock after purchasing an additional 881,155 shares during the period. Grifols accounts for 2.9% of Black Creek Investment Management Inc.’s portfolio, making the stock its 12th largest position. Black Creek Investment Management Inc. owned about 1.79% of Grifols worth $77,799,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently made changes to their positions in the stock. International Assets Investment Management LLC purchased a new position in Grifols in the fourth quarter valued at approximately $398,000. BNP Paribas Financial Markets boosted its position in shares of Grifols by 20.0% in the fourth quarter. BNP Paribas Financial Markets now owns 138,915 shares of the biotechnology company’s stock worth $1,606,000 after buying an additional 23,122 shares during the period. Jump Financial LLC grew its stake in shares of Grifols by 215.0% in the fourth quarter. Jump Financial LLC now owns 46,727 shares of the biotechnology company’s stock valued at $540,000 after buying an additional 31,891 shares in the last quarter. QRG Capital Management Inc. raised its holdings in shares of Grifols by 5.9% during the 4th quarter. QRG Capital Management Inc. now owns 35,116 shares of the biotechnology company’s stock valued at $406,000 after buying an additional 1,964 shares during the period. Finally, Norges Bank purchased a new stake in shares of Grifols during the 4th quarter valued at about $26,137,000.

Grifols Stock Performance

NASDAQ GRFS opened at $9.26 on Monday. The company has a debt-to-equity ratio of 1.06, a quick ratio of 0.80 and a current ratio of 1.68. Grifols, S.A. has a fifty-two week low of $5.30 and a fifty-two week high of $12.15. The business has a 50 day moving average price of $8.12 and a two-hundred day moving average price of $7.27.

Grifols (NASDAQ:GRFS) last announced its earnings results on Tuesday, July 30th. The biotechnology company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.23 by ($0.21). The firm had revenue of $1.96 billion during the quarter. Grifols had a net margin of 0.90% and a return on equity of 1.73%. On average, equities analysts predict that Grifols, S.A. will post 0.79 EPS for the current fiscal year.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.